Cilengitide (EMD121974) in Combination With Whole Brain Radiotherapy in Patients With Brain Metastases From Lung Cancer - a Single-Center, Open-Label Phase I Study.

Trial Profile

Cilengitide (EMD121974) in Combination With Whole Brain Radiotherapy in Patients With Brain Metastases From Lung Cancer - a Single-Center, Open-Label Phase I Study.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Cilengitide (Primary)
  • Indications Cancer metastases; Non-small cell lung cancer; Small cell lung cancer
  • Focus Adverse reactions
  • Acronyms CIRAB
  • Most Recent Events

    • 03 May 2010 Planned end date changed from 1 Feb 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 20 May 2009 Trial acronym (CIRAB) added as reported by ClinicalTrials.gov.
    • 23 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top